SCHEMBL21294322

SCHEMBL21294322

O=C(O)CCCCCCCCCOc1ccc(C(=O)OCc2ccccc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.63
SLC6A2 P23975 1/20 0.58
SLC6A3 Q01959 1/20 0.58
KMT2A Q03164 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
LMNA P02545 1/20 0.57
FFAR1 O14842 4/20 0.55
ESR1 P03372 1/20 0.52
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
HTT P42858 1/20 0.51
S1PR1 P21453 2/20 0.50
ALB P02768 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
NR4A1 P22736 1/20 0.50
NR4A2 P43354 1/20 0.50
NR4A3 Q92570 1/20 0.50
S1PR3 Q99500 1/20 0.50
S1PR5 Q9H228 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20672958 1.00 PPARA (0.63) PPARASLC6A2SLC6A3KMT2ATDP1
SCHEMBL9629906 0.88 TDP1 (0.59) SLC6A2SLC6A3KMT2ATDP1LMNA
SCHEMBL51012 0.87 KMT2A (0.71) SLC6A2SLC6A3KMT2ATDP1LMNA
SCHEMBL1171933 0.86 FFAR1 (0.67) PPARAFFAR1HTTALBFFAR4
SCHEMBL1799635 0.86 FFAR1 (0.67) PPARAFFAR1HTTALBFFAR4
SCHEMBL1171526 0.86 FFAR1 (0.67) PPARAFFAR1HTTALBFFAR4
SCHEMBL20830500 0.85 TSHR (0.62) SLC6A2SLC6A3KMT2ATDP1LMNA
SCHEMBL20830910 0.85 TSHR (0.65) SLC6A2SLC6A3KMT2ATDP1LMNA
SCHEMBL21980210 0.84 LMNA (0.49) PPARASLC6A2SLC6A3KMT2ATDP1
SCHEMBL9780443 0.84 SLC6A2 (0.55) SLC6A2SLC6A3KMT2ATDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787837-B2 DCHBS-active esters of PEG compounds and their use NOVO NORDISK A/S (DK) 2023-10-17 US disclosed
CN-109922835-B DCHBS active ester of PEG compound and application thereof 诺和诺德股份有限公司 2023-08-04 CN disclosed
WO-2022090448-A1 NOVEL ACYLATING REAGENTS NOVO NORDISK A/S (DK) 2022-05-05 WO disclosed
EP-3534962-B1 DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE NOVO NORDISK AS (DK) 2020-08-19 EP disclosed
EP-3534962-A1 DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE Novo Nordisk A/S (DK) 2019-09-11 EP disclosed
US-20190263854-A1 DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE NOVO NORDISK A/S (DK) 2019-08-29 US disclosed
CN-109922835-A The PEGylated DCHBS active ester and application thereof for closing object 诺和诺德股份有限公司 2019-06-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263854-A1 DCHBS-ACTIVE ESTERS OF PEG COMPOUNDS AND THEIR USE HBB, IAPP, GLP1R PPARA 284/4885SLC6A2 4410/4885SLC6A3 3820/4885
US-11787837-B2 DCHBS-active esters of PEG compounds and their use HBB, IAPP, GLP1R PPARA 284/4885SLC6A2 4410/4885SLC6A3 3820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.